| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antihypertensive Agents | 21 | 2021 | 351 | 4.200 |
Why?
|
| Hypertension | 20 | 2021 | 956 | 3.180 |
Why?
|
| Blood Pressure | 20 | 2021 | 843 | 3.010 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 404 | 2.020 |
Why?
|
| Blood Pressure Determination | 8 | 2019 | 100 | 1.850 |
Why?
|
| Cardiology | 3 | 2018 | 99 | 1.670 |
Why?
|
| Ferritins | 15 | 2020 | 46 | 1.650 |
Why?
|
| Hemochromatosis | 20 | 2009 | 70 | 1.640 |
Why?
|
| American Heart Association | 3 | 2018 | 87 | 1.320 |
Why?
|
| Weight Loss | 14 | 2021 | 465 | 1.270 |
Why?
|
| Transferrin | 12 | 2020 | 33 | 1.260 |
Why?
|
| Histocompatibility Antigens Class I | 17 | 2009 | 59 | 1.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2017 | 1424 | 0.910 |
Why?
|
| Membrane Proteins | 17 | 2009 | 257 | 0.910 |
Why?
|
| Iron Overload | 13 | 2009 | 38 | 0.900 |
Why?
|
| Sleep Apnea, Obstructive | 7 | 2021 | 58 | 0.860 |
Why?
|
| Humans | 114 | 2021 | 31836 | 0.830 |
Why?
|
| Middle Aged | 73 | 2021 | 11824 | 0.790 |
Why?
|
| Female | 93 | 2021 | 19859 | 0.750 |
Why?
|
| Aged | 61 | 2021 | 10288 | 0.730 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 9 | 0.720 |
Why?
|
| Dementia | 2 | 2019 | 251 | 0.680 |
Why?
|
| Life Style | 10 | 2021 | 407 | 0.680 |
Why?
|
| Ethnic Groups | 6 | 2021 | 476 | 0.680 |
Why?
|
| Male | 81 | 2021 | 19091 | 0.670 |
Why?
|
| Cardiovascular Diseases | 13 | 2021 | 1122 | 0.640 |
Why?
|
| Advisory Committees | 1 | 2017 | 31 | 0.610 |
Why?
|
| Adult | 47 | 2021 | 9327 | 0.590 |
Why?
|
| Disease Management | 1 | 2017 | 126 | 0.560 |
Why?
|
| Electroconvulsive Therapy | 5 | 2012 | 28 | 0.550 |
Why?
|
| Estrogen Replacement Therapy | 10 | 2008 | 187 | 0.500 |
Why?
|
| United States | 14 | 2020 | 3925 | 0.490 |
Why?
|
| Obesity | 10 | 2020 | 1158 | 0.470 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2018 | 288 | 0.470 |
Why?
|
| Models, Statistical | 4 | 2021 | 173 | 0.430 |
Why?
|
| Polymorphism, Genetic | 5 | 2010 | 184 | 0.430 |
Why?
|
| Mutation | 10 | 2020 | 487 | 0.420 |
Why?
|
| Iron | 9 | 2009 | 115 | 0.410 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 297 | 0.400 |
Why?
|
| Data Interpretation, Statistical | 3 | 2000 | 109 | 0.340 |
Why?
|
| Severity of Illness Index | 16 | 2021 | 899 | 0.330 |
Why?
|
| Genotype | 16 | 2010 | 727 | 0.310 |
Why?
|
| Homozygote | 10 | 2009 | 58 | 0.310 |
Why?
|
| Brain | 5 | 2019 | 949 | 0.300 |
Why?
|
| Cation Transport Proteins | 2 | 2007 | 24 | 0.300 |
Why?
|
| Treatment Outcome | 13 | 2021 | 3294 | 0.300 |
Why?
|
| Coronary Disease | 5 | 2012 | 213 | 0.300 |
Why?
|
| Mass Screening | 8 | 2009 | 263 | 0.290 |
Why?
|
| Overweight | 5 | 2017 | 276 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 504 | 0.280 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2007 | 227 | 0.280 |
Why?
|
| Seizures | 3 | 1998 | 64 | 0.280 |
Why?
|
| Psoriasis | 8 | 1999 | 360 | 0.280 |
Why?
|
| Multicenter Studies as Topic | 3 | 2009 | 103 | 0.280 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 2271 | 0.270 |
Why?
|
| Postmenopause | 9 | 2009 | 413 | 0.260 |
Why?
|
| Coronary Artery Disease | 5 | 2008 | 398 | 0.250 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 3988 | 0.250 |
Why?
|
| Risk Factors | 14 | 2019 | 3851 | 0.250 |
Why?
|
| Risk Reduction Behavior | 3 | 2018 | 125 | 0.250 |
Why?
|
| Diet, Reducing | 3 | 2014 | 102 | 0.250 |
Why?
|
| Carbamates | 1 | 2004 | 15 | 0.240 |
Why?
|
| Metformin | 1 | 2004 | 22 | 0.240 |
Why?
|
| Mental Disorders | 3 | 2003 | 121 | 0.240 |
Why?
|
| European Continental Ancestry Group | 7 | 2009 | 1169 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 1323 | 0.240 |
Why?
|
| Estrogens, Conjugated (USP) | 5 | 2009 | 128 | 0.230 |
Why?
|
| Prevalence | 7 | 2020 | 979 | 0.230 |
Why?
|
| Piperidines | 1 | 2004 | 117 | 0.230 |
Why?
|
| Cholesterol, HDL | 4 | 2012 | 177 | 0.230 |
Why?
|
| Decision Support Techniques | 1 | 2005 | 128 | 0.230 |
Why?
|
| Medroxyprogesterone Acetate | 5 | 2009 | 93 | 0.230 |
Why?
|
| Electroencephalography | 4 | 1998 | 72 | 0.220 |
Why?
|
| Internet | 1 | 2005 | 195 | 0.220 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 181 | 0.220 |
Why?
|
| Canada | 3 | 2020 | 56 | 0.220 |
Why?
|
| Comorbidity | 4 | 2018 | 566 | 0.220 |
Why?
|
| Adolescent Health Services | 1 | 2003 | 12 | 0.220 |
Why?
|
| Research Design | 4 | 2003 | 310 | 0.210 |
Why?
|
| Aftercare | 1 | 2003 | 31 | 0.210 |
Why?
|
| Mental Health Services | 1 | 2003 | 28 | 0.210 |
Why?
|
| Genetic Testing | 5 | 2009 | 96 | 0.210 |
Why?
|
| Polysomnography | 7 | 2021 | 40 | 0.210 |
Why?
|
| Suicide, Attempted | 5 | 2001 | 32 | 0.200 |
Why?
|
| Quality of Life | 7 | 2012 | 924 | 0.190 |
Why?
|
| Cerebrovascular Circulation | 3 | 1998 | 92 | 0.190 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 251 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 1527 | 0.190 |
Why?
|
| Health Services Accessibility | 1 | 2003 | 242 | 0.180 |
Why?
|
| Sleep, REM | 2 | 2017 | 6 | 0.180 |
Why?
|
| Exercise | 4 | 2013 | 663 | 0.180 |
Why?
|
| Adolescent | 14 | 2021 | 3511 | 0.180 |
Why?
|
| Biometry | 1 | 1999 | 13 | 0.170 |
Why?
|
| Echo-Planar Imaging | 1 | 1999 | 15 | 0.170 |
Why?
|
| Cognition | 2 | 2020 | 551 | 0.170 |
Why?
|
| Cerebral Infarction | 1 | 1999 | 22 | 0.170 |
Why?
|
| Mass Media | 1 | 2019 | 11 | 0.170 |
Why?
|
| Cause of Death | 2 | 2017 | 238 | 0.170 |
Why?
|
| Image Enhancement | 1 | 1999 | 72 | 0.170 |
Why?
|
| Thyroxine | 2 | 2009 | 16 | 0.170 |
Why?
|
| Disabled Persons | 1 | 1999 | 105 | 0.160 |
Why?
|
| Consensus | 1 | 2018 | 85 | 0.160 |
Why?
|
| Lipoproteins | 2 | 2009 | 84 | 0.160 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 589 | 0.160 |
Why?
|
| Risk Assessment | 8 | 2018 | 1431 | 0.150 |
Why?
|
| Patient Care Planning | 2 | 2017 | 59 | 0.150 |
Why?
|
| Sleep | 2 | 2014 | 92 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 1997 | 51 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 215 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 1 | 1997 | 24 | 0.140 |
Why?
|
| Cerebral Hemorrhage | 1 | 1997 | 68 | 0.140 |
Why?
|
| Dental Implantation, Endosseous | 1 | 1996 | 4 | 0.130 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2016 | 16 | 0.130 |
Why?
|
| Dental Implants | 1 | 1996 | 6 | 0.130 |
Why?
|
| Triglycerides | 5 | 2009 | 230 | 0.130 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 756 | 0.130 |
Why?
|
| Sports Medicine | 1 | 1996 | 22 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2010 | 239 | 0.130 |
Why?
|
| Mandible | 1 | 1996 | 39 | 0.130 |
Why?
|
| Fractures, Bone | 1 | 2017 | 144 | 0.130 |
Why?
|
| Brachial Artery | 2 | 2007 | 69 | 0.130 |
Why?
|
| Vasodilation | 2 | 2007 | 92 | 0.130 |
Why?
|
| Physical Fitness | 1 | 2016 | 131 | 0.120 |
Why?
|
| Scapula | 1 | 1995 | 18 | 0.120 |
Why?
|
| Heart Failure | 2 | 2017 | 620 | 0.120 |
Why?
|
| Body Mass Index | 6 | 2016 | 916 | 0.120 |
Why?
|
| Time Factors | 6 | 2017 | 2146 | 0.120 |
Why?
|
| Aging | 2 | 1999 | 941 | 0.120 |
Why?
|
| Cocaine | 2 | 1995 | 256 | 0.120 |
Why?
|
| Caffeine | 1 | 1994 | 29 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 1997 | 327 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 251 | 0.110 |
Why?
|
| Intracranial Embolism and Thrombosis | 3 | 1998 | 3 | 0.110 |
Why?
|
| Software | 3 | 2005 | 127 | 0.110 |
Why?
|
| Cardiopulmonary Bypass | 3 | 1998 | 57 | 0.110 |
Why?
|
| Estrogens | 2 | 2007 | 167 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2003 | 2277 | 0.110 |
Why?
|
| Shoulder Joint | 1 | 1995 | 126 | 0.110 |
Why?
|
| Behavior, Animal | 1 | 1994 | 250 | 0.110 |
Why?
|
| Depressive Disorder, Major | 1 | 2012 | 42 | 0.100 |
Why?
|
| Apolipoproteins | 1 | 2014 | 200 | 0.100 |
Why?
|
| Logistic Models | 4 | 2006 | 777 | 0.100 |
Why?
|
| Receptors, Estrogen | 2 | 2002 | 103 | 0.100 |
Why?
|
| Internship and Residency | 1 | 1995 | 306 | 0.100 |
Why?
|
| Potassium, Dietary | 2 | 2001 | 5 | 0.100 |
Why?
|
| Cholesterol | 3 | 2008 | 251 | 0.100 |
Why?
|
| Stroke | 2 | 2017 | 581 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 143 | 0.100 |
Why?
|
| Sodium, Dietary | 2 | 2001 | 23 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 912 | 0.090 |
Why?
|
| International Cooperation | 1 | 2010 | 28 | 0.090 |
Why?
|
| Child | 7 | 2003 | 2425 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2009 | 835 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2010 | 40 | 0.090 |
Why?
|
| Phenotype | 6 | 2009 | 635 | 0.090 |
Why?
|
| Asian Americans | 2 | 2007 | 97 | 0.090 |
Why?
|
| Erythrocyte Count | 1 | 2009 | 4 | 0.090 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2020 | 28 | 0.090 |
Why?
|
| North Carolina | 4 | 2003 | 1514 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2018 | 487 | 0.080 |
Why?
|
| Age Factors | 5 | 2018 | 1187 | 0.080 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2009 | 56 | 0.080 |
Why?
|
| DNA | 2 | 2008 | 227 | 0.080 |
Why?
|
| Hormones | 1 | 2008 | 21 | 0.080 |
Why?
|
| Indians, North American | 2 | 2006 | 109 | 0.080 |
Why?
|
| Liver Diseases | 2 | 2006 | 70 | 0.080 |
Why?
|
| Behavior Therapy | 1 | 2009 | 102 | 0.080 |
Why?
|
| Thyrotropin | 1 | 2008 | 8 | 0.080 |
Why?
|
| Observer Variation | 3 | 1998 | 105 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2004 | 284 | 0.080 |
Why?
|
| Young Adult | 3 | 2021 | 2603 | 0.080 |
Why?
|
| Adolescent Behavior | 2 | 1999 | 61 | 0.080 |
Why?
|
| Patient Education as Topic | 3 | 2016 | 271 | 0.080 |
Why?
|
| Iron-Binding Proteins | 1 | 2007 | 4 | 0.080 |
Why?
|
| Erythrocyte Indices | 1 | 2007 | 4 | 0.080 |
Why?
|
| Albuminuria | 1 | 2009 | 181 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2007 | 47 | 0.080 |
Why?
|
| Prognosis | 3 | 2018 | 1498 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 1067 | 0.070 |
Why?
|
| Health Status | 2 | 2016 | 397 | 0.070 |
Why?
|
| Oceanic Ancestry Group | 1 | 2007 | 7 | 0.070 |
Why?
|
| Contraceptive Agents, Female | 1 | 2007 | 15 | 0.070 |
Why?
|
| E-Selectin | 2 | 2008 | 20 | 0.070 |
Why?
|
| Sleep Apnea Syndromes | 2 | 1998 | 27 | 0.070 |
Why?
|
| Coronary Angiography | 5 | 2008 | 148 | 0.070 |
Why?
|
| Hospitalization | 3 | 2001 | 463 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 1997 | 665 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 305 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 874 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2007 | 189 | 0.070 |
Why?
|
| Continental Population Groups | 1 | 2007 | 236 | 0.070 |
Why?
|
| Anthropometry | 2 | 2017 | 83 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 629 | 0.070 |
Why?
|
| Systole | 2 | 2017 | 99 | 0.070 |
Why?
|
| Sex Factors | 4 | 2018 | 662 | 0.060 |
Why?
|
| African Continental Ancestry Group | 2 | 2005 | 363 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1192 | 0.060 |
Why?
|
| Forecasting | 2 | 2003 | 144 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 2 | 2002 | 88 | 0.060 |
Why?
|
| Double-Blind Method | 5 | 2007 | 523 | 0.060 |
Why?
|
| African Americans | 2 | 2014 | 1428 | 0.060 |
Why?
|
| Reference Standards | 2 | 2017 | 32 | 0.060 |
Why?
|
| Adaptation, Psychological | 2 | 2003 | 136 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2004 | 181 | 0.060 |
Why?
|
| Nutritional Status | 2 | 2001 | 75 | 0.060 |
Why?
|
| Microcirculation | 3 | 1998 | 65 | 0.060 |
Why?
|
| Utilization Review | 1 | 2003 | 17 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 409 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 564 | 0.050 |
Why?
|
| Patient Selection | 2 | 2003 | 276 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2012 | 470 | 0.050 |
Why?
|
| Factor V | 1 | 2002 | 7 | 0.050 |
Why?
|
| Depressive Disorder | 2 | 2000 | 75 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2002 | 34 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2002 | 49 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 2 | 2017 | 540 | 0.050 |
Why?
|
| Gene Frequency | 3 | 2007 | 220 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 1998 | 78 | 0.050 |
Why?
|
| Women's Health | 1 | 2003 | 235 | 0.050 |
Why?
|
| Reference Values | 2 | 2014 | 247 | 0.050 |
Why?
|
| Ethanol | 1 | 2003 | 186 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2017 | 491 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 28 | 0.050 |
Why?
|
| Problem Solving | 1 | 2001 | 28 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 247 | 0.050 |
Why?
|
| Heliotherapy | 2 | 1997 | 3 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2001 | 771 | 0.050 |
Why?
|
| Social Environment | 1 | 2001 | 79 | 0.050 |
Why?
|
| Histocytochemistry | 2 | 1998 | 30 | 0.050 |
Why?
|
| Alkaline Phosphatase | 2 | 1998 | 38 | 0.050 |
Why?
|
| Medroxyprogesterone | 1 | 2000 | 14 | 0.050 |
Why?
|
| Progesterone Congeners | 1 | 2000 | 15 | 0.050 |
Why?
|
| Lipids | 2 | 2000 | 228 | 0.050 |
Why?
|
| Liver | 1 | 2003 | 482 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 62 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 122 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 1999 | 48 | 0.040 |
Why?
|
| Self Administration | 3 | 1997 | 297 | 0.040 |
Why?
|
| California | 1 | 1999 | 61 | 0.040 |
Why?
|
| Memory | 1 | 2001 | 190 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 1999 | 73 | 0.040 |
Why?
|
| Waist Circumference | 2 | 2009 | 90 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 208 | 0.040 |
Why?
|
| Placebos | 2 | 2008 | 63 | 0.040 |
Why?
|
| Adolescent, Hospitalized | 1 | 1998 | 2 | 0.040 |
Why?
|
| Acute Disease | 1 | 1999 | 252 | 0.040 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1998 | 4 | 0.040 |
Why?
|
| Suction | 1 | 1998 | 10 | 0.040 |
Why?
|
| Reproducibility of Results | 4 | 2006 | 764 | 0.040 |
Why?
|
| Sleep Stages | 2 | 2014 | 6 | 0.040 |
Why?
|
| Silicon | 1 | 1998 | 2 | 0.040 |
Why?
|
| Aluminum | 1 | 1998 | 5 | 0.040 |
Why?
|
| Urban Population | 1 | 1998 | 89 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2008 | 50 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 148 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 1997 | 11 | 0.040 |
Why?
|
| Chronic Disease | 1 | 1999 | 400 | 0.040 |
Why?
|
| Receptors, Transferrin | 2 | 2008 | 10 | 0.040 |
Why?
|
| Gastric Acidity Determination | 1 | 1997 | 4 | 0.040 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2008 | 14 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 1997 | 10 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 1998 | 140 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1998 | 73 | 0.040 |
Why?
|
| Liver Function Tests | 2 | 2007 | 22 | 0.040 |
Why?
|
| Gastroesophageal Reflux | 1 | 1997 | 25 | 0.040 |
Why?
|
| Cerebral Arteries | 1 | 1997 | 18 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 272 | 0.040 |
Why?
|
| Office Visits | 1 | 2017 | 73 | 0.040 |
Why?
|
| Veins | 1 | 1997 | 29 | 0.040 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 1997 | 48 | 0.040 |
Why?
|
| Recurrence | 3 | 2008 | 262 | 0.040 |
Why?
|
| Rural Population | 1 | 1998 | 273 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2000 | 384 | 0.040 |
Why?
|
| Infant, Premature | 1 | 1997 | 68 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 107 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2008 | 195 | 0.030 |
Why?
|
| Home Nursing | 1 | 1996 | 10 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2008 | 895 | 0.030 |
Why?
|
| Animals | 6 | 2003 | 7450 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 1996 | 18 | 0.030 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2016 | 5 | 0.030 |
Why?
|
| Alveolectomy | 1 | 1996 | 1 | 0.030 |
Why?
|
| Incisor | 1 | 1996 | 1 | 0.030 |
Why?
|
| Jaw, Edentulous | 1 | 1996 | 2 | 0.030 |
Why?
|
| Bicuspid | 1 | 1996 | 2 | 0.030 |
Why?
|
| Molar | 1 | 1996 | 4 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 2 | 2009 | 50 | 0.030 |
Why?
|
| Alveolar Process | 1 | 1996 | 5 | 0.030 |
Why?
|
| Titanium | 1 | 1996 | 9 | 0.030 |
Why?
|
| Subtraction Technique | 1 | 1996 | 10 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 1996 | 26 | 0.030 |
Why?
|
| Ultraviolet Therapy | 1 | 1996 | 40 | 0.030 |
Why?
|
| Patient Admission | 1 | 1996 | 60 | 0.030 |
Why?
|
| Complementary Therapies | 1 | 1996 | 80 | 0.030 |
Why?
|
| Goals | 1 | 2015 | 36 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2003 | 293 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 193 | 0.030 |
Why?
|
| Apnea | 1 | 2014 | 6 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 1995 | 124 | 0.030 |
Why?
|
| Depression | 2 | 2012 | 442 | 0.030 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.030 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 11 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 1994 | 16 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 48 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 61 | 0.030 |
Why?
|
| Reinforcement Schedule | 1 | 1994 | 57 | 0.030 |
Why?
|
| Nucleus Accumbens | 1 | 1995 | 94 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 99 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1994 | 201 | 0.030 |
Why?
|
| Conditioning, Operant | 1 | 1994 | 88 | 0.030 |
Why?
|
| Diet | 2 | 2012 | 385 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 135 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 449 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2014 | 245 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 1994 | 285 | 0.030 |
Why?
|
| Dogs | 3 | 1998 | 116 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2013 | 162 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 480 | 0.030 |
Why?
|
| Disease Progression | 2 | 2008 | 593 | 0.030 |
Why?
|
| Remission Induction | 1 | 2012 | 84 | 0.030 |
Why?
|
| Motor Activity | 1 | 1995 | 325 | 0.030 |
Why?
|
| Dopamine | 1 | 1995 | 232 | 0.030 |
Why?
|
| Primary Health Care | 2 | 2006 | 225 | 0.030 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 155 | 0.030 |
Why?
|
| Heart Rate | 1 | 1994 | 332 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 1995 | 249 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2013 | 161 | 0.020 |
Why?
|
| Sodium | 2 | 2001 | 38 | 0.020 |
Why?
|
| Weight Gain | 1 | 2012 | 116 | 0.020 |
Why?
|
| Potassium | 2 | 2001 | 38 | 0.020 |
Why?
|
| Biological Assay | 1 | 2010 | 19 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 23 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 43 | 0.020 |
Why?
|
| Education | 1 | 2010 | 39 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 140 | 0.020 |
Why?
|
| North America | 1 | 2009 | 32 | 0.020 |
Why?
|
| Cell Size | 1 | 2009 | 38 | 0.020 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2009 | 11 | 0.020 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2009 | 12 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1994 | 632 | 0.020 |
Why?
|
| Lipoprotein Lipase | 1 | 2009 | 14 | 0.020 |
Why?
|
| Lipase | 1 | 2009 | 27 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 104 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 60 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 41 | 0.020 |
Why?
|
| Attitude to Health | 2 | 2003 | 165 | 0.020 |
Why?
|
| Hyperthyroidism | 1 | 2008 | 2 | 0.020 |
Why?
|
| Epidemiologic Measurements | 1 | 2008 | 2 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 1999 | 107 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2008 | 1824 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2008 | 11 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2008 | 16 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 206 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2008 | 40 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 248 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 306 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 158 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2007 | 124 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2007 | 94 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 208 | 0.020 |
Why?
|
| Apoferritins | 1 | 2007 | 4 | 0.020 |
Why?
|
| Arterioles | 2 | 1998 | 13 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 86 | 0.020 |
Why?
|
| Capillaries | 2 | 1998 | 24 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2007 | 108 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 495 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 72 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 20 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 45 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2009 | 345 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 884 | 0.020 |
Why?
|
| ROC Curve | 1 | 2005 | 167 | 0.020 |
Why?
|
| Arthritis | 1 | 2005 | 40 | 0.020 |
Why?
|
| Protein Binding | 1 | 2005 | 201 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2007 | 378 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2005 | 115 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 177 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 2003 | 8 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 2003 | 47 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 42 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2003 | 397 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 135 | 0.010 |
Why?
|
| Social Support | 1 | 2003 | 180 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 251 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2001 | 20 | 0.010 |
Why?
|
| Health Behavior | 1 | 2003 | 231 | 0.010 |
Why?
|
| Urinalysis | 1 | 2001 | 27 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 318 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2001 | 22 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2001 | 100 | 0.010 |
Why?
|
| Affect | 1 | 2001 | 69 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 1998 | 3488 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2000 | 56 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2001 | 136 | 0.010 |
Why?
|
| Memory Disorders | 1 | 2000 | 54 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2001 | 183 | 0.010 |
Why?
|
| Virginia | 1 | 1999 | 63 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 1998 | 20 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 1998 | 17 | 0.010 |
Why?
|
| Vasculitis | 1 | 1998 | 23 | 0.010 |
Why?
|
| Lasers | 1 | 1998 | 21 | 0.010 |
Why?
|
| Work | 1 | 1997 | 6 | 0.010 |
Why?
|
| Financing, Personal | 1 | 1997 | 6 | 0.010 |
Why?
|
| Absenteeism | 1 | 1997 | 11 | 0.010 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 1998 | 37 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1998 | 103 | 0.010 |
Why?
|
| Family Characteristics | 1 | 1997 | 35 | 0.010 |
Why?
|
| Self Concept | 1 | 1997 | 42 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 65 | 0.010 |
Why?
|
| Cost of Illness | 1 | 1997 | 70 | 0.010 |
Why?
|
| Income | 1 | 1997 | 61 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1997 | 50 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 1998 | 100 | 0.010 |
Why?
|
| Health Expenditures | 1 | 1997 | 66 | 0.010 |
Why?
|
| Phytotherapy | 1 | 1996 | 38 | 0.010 |
Why?
|
| Crisis Intervention | 1 | 1996 | 1 | 0.010 |
Why?
|
| Personality Assessment | 1 | 1996 | 9 | 0.010 |
Why?
|
| Self Care | 1 | 1997 | 144 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1997 | 117 | 0.010 |
Why?
|
| Smoking | 1 | 2000 | 499 | 0.010 |
Why?
|
| Arthritis, Psoriatic | 1 | 1996 | 25 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1997 | 257 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1997 | 420 | 0.010 |
Why?
|
| Vitamins | 1 | 1996 | 68 | 0.010 |
Why?
|
| Electrooculography | 1 | 1995 | 2 | 0.010 |
Why?
|
| Arousal | 1 | 1995 | 19 | 0.010 |
Why?
|
| Data Collection | 1 | 1996 | 180 | 0.010 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1995 | 3 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1997 | 240 | 0.010 |
Why?
|
| Homovanillic Acid | 1 | 1995 | 11 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1996 | 77 | 0.010 |
Why?
|
| Skin | 1 | 1997 | 210 | 0.010 |
Why?
|
| Mortality | 1 | 1996 | 124 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1995 | 133 | 0.010 |
Why?
|
| Length of Stay | 1 | 1996 | 315 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1996 | 537 | 0.010 |
Why?
|
| Infant | 1 | 1997 | 1055 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1997 | 1259 | 0.010 |
Why?
|
| Rats | 1 | 1995 | 1586 | 0.010 |
Why?
|